Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Sartorius Stedim Biotech    DIM   FR0013154002

SARTORIUS STEDIM BIOTECH

(DIM)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Sartorius Stedim Biotech : successfully places note loan with a volume of 750...

share with twitter share with LinkedIn share with facebook
09/09/2020 | 09:10am EDT

Press Release

Göttingen, September 9, 2020

Sartorius successfully places note loan with a volume of 750 million euros

  • Transaction oversubscribed more than three times
  • Volume increased from 300 million euros to 750 million euros

Sartorius, a leading international partner of life science research and the biopharmaceutical industry, successfully placed a note loan with a volume of 750 million euros. The note loan was issued with maturity terms of 3, 5, 7 and 10 years and was significantly oversubscribed. "We see such great interest as clear proof of our attractiveness for investors," said Rainer Lehmann, Chief Financial Officer of Sartorius.

In view of high demand, the targeted minimum volume of 300 million euros was significantly exceeded. Most of the funds will be used for early repayment of the bridge loan that Sartorius had taken out at the end of April in connection with the acquisition of selected life science businesses from Danaher.

This press release contains forward-looking statements about the future development of the Sartorius Group. Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by such statements. Sartorius assumes no liability for updating such statements in light of new information or future events. This is a translation of the original German-language press release. Sartorius shall not assume any liability for the correctness of this translation. The original German press release is the legally binding version.

A profile of Sartorius

The Sartorius Group is a leading international partner of life science research and the biopharmaceutical industry. With innovative laboratory instruments and consumables, the Group's Lab Products & Services Division concentrates on serving the needs of laboratories performing research and quality control at pharma and biopharma companies and those of academic research institutes. The Bioprocess Solutions Division with its broad product portfolio focusing on single-use solutions helps customers to manufacture biotech medications and vaccines safely and efficiently. The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions of complementary technologies. In fiscal 2019, the company earned sales revenue of some 1.83 billion euros. At the end of 2019, more than 9,000 people were employed at the Group's approximately 60 manufacturing and sales sites, serving customers around the globe.

Contact

Timo Lindemann Corporate Communications +49 (0)551.308.4724 timo.lindemann@sartorius.comsartorius.com

Follow Sartorius on Twitter @Sartorius_Groupand on LinkedIn.

1 | 1

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Sartorius Stedim Biotech SA published this content on 09 September 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 09 September 2020 12:09:03 UTC


share with twitter share with LinkedIn share with facebook
All news about SARTORIUS STEDIM BIOTECH
10/20SARTORIUS STEDIM BIOTECH : Conference Call 9M|2020 Presentation
PU
10/20SARTORIUS STEDIM BIOTECH : Earnings Release 9M|2020
PU
10/20SARTORIUS STEDIM BIOTECH : Strong profitable growth at Sartorius Stedim Biotech
PU
10/20SARTORIUS STEDIM BIOTECH : Strong profitable growth at Sartorius
PU
10/20SARTORIUS STEDIM BIOTECH : Strong profitable growth at Sartorius Stedim Biotech
PR
10/20SARTORIUS STEDIM BIOTECH : 3rd quarter results
CO
10/20SARTORIUS STEDIM BIOTECH : Press Release
CO
10/15SARTORIUS STEDIM BIOTECH : quaterly earnings release
10/02SARTORIUS STEDIM BIOTECH : Purification specialist BIA Separations to become par..
PU
10/02SARTORIUS STEDIM BIOTECH : Purification specialist BIA Separations to become par..
PU
More news
Financials
Sales 2020 1 878 M 2 192 M 2 192 M
Net income 2020 353 M 412 M 412 M
Net Debt 2020 302 M 352 M 352 M
P/E ratio 2020 85,7x
Yield 2020 0,29%
Capitalization 30 051 M 35 041 M 35 073 M
EV / Sales 2020 16,2x
EV / Sales 2021 13,4x
Nbr of Employees 6 979
Free-Float 25,7%
Chart SARTORIUS STEDIM BIOTECH
Duration : Period :
Sartorius Stedim Biotech Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SARTORIUS STEDIM BIOTECH
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 8
Average target price 281,38 €
Last Close Price 325,40 €
Spread / Highest target 19,2%
Spread / Average Target -13,5%
Spread / Lowest Target -45,6%
EPS Revisions
Managers
NameTitle
Joachim Kreuzburg Chairman & Chief Executive Officer
Volker Niebel Executive VP-Operations & Information Technology
Oscar-Werner Reif Executive VP-Research & Development
Henri Riey Independent Non-Executive Director
Anne-Marie Graffin Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
SARTORIUS STEDIM BIOTECH120.31%35 264
ABBOTT LABORATORIES22.52%188 420
MEDTRONIC PLC-9.57%137 923
BECTON, DICKINSON AND COMPANY-13.27%68 377
HOYA CORPORATION20.86%45 978
BAXTER INTERNATIONAL INC.-6.54%39 562